1 / 1

Assessment of Mitochondrial Membrane Potential Loss in Jurkat Cells Under Different Treatments

This study examines the loss of mitochondrial membrane potential over time in Jurkat-derived cells treated with anti-CD95 and etoposide. Cells were analyzed at 0, 4, or 12 hours after treatment, with and without the pan-caspase inhibitor z-VAD-fmk (100 μM final concentration), and also after a 20-hour incubation without z-VAD-fmk. Mitochondrial membrane potential was assessed using tetramethylrhodamine methyl ester (TMRM), and fluorescence quantification was performed via flow cytometry to determine treatment effects on cellular health.

tauret
Télécharger la présentation

Assessment of Mitochondrial Membrane Potential Loss in Jurkat Cells Under Different Treatments

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Supplemental Figure 1. Loss of mitochondrial membrane potential over time. Jurkat derived cells were treated with anti-CD95 (left) or etoposide (right) for 0, 4, or 12 h in both the absence (closed symbols) or presence (open symbols) of the pan-caspase inhibitor z-VAD-fmk (100 mM final), or for 20 h in the absence of z-VAD-fmk. Following treatment, cells were incubated with tetramethylrhodamine methyl ester (TMRM), and fluorescence was subsequently quantified by flow cytometry.

More Related